NEW YORK (GenomeWeb) – Enzo Biochem today reported flat year-over-year revenues for its fiscal third quarter. 

For the three months ended April 30, the firm recorded total revenues of $24 million, the same as a year ago. Enzo Clinical Labs' revenues were up 8 percent to $15.7 million from $14.5 million, but Life Sciences revenues, which comprise Enzo's product revenues, slid 9 percent to $7.9 million from $8.7 million due to the effects of currency exchange and the timing of customer reordering patterns, Enzo said. Royalty and license fee income dropped to $423,000 from $729,000. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.